Elon Musk's X Corp files a major antitrust lawsuit against 18 music publishers, alleging a conspiracy to inflate licensing fees. The platform claims it was forced to remove thousands of posts and suspend users.
Google, Meta, Amazon, Microsoft, and Netflix will face voluntary rules under EU's Digital Networks Act, not binding regulations. The new framework aims to boost telecom investment. Read the details.
Explore the high-stakes legal battles between Indian generic manufacturers and global pharma giants. Understand the impact on drug prices, accessibility, and the evolving IP landscape in India.
India plans a major pharma licensing overhaul with a separate wholesale licence for bulk drugs and APIs to improve traceability and safety. This move follows global scrutiny over contaminated cough syrups and aims to regulate a $50-billion market.
Indian pharmaceutical companies, long known for generics, saw their risky innovation bets yield major commercial success in 2025 through global deals and approvals. Discover the key players and what's next for 2026.
India plans a new wholesale licensing system for bulk drugs and a supplier database to enhance traceability and accountability in its $50-billion pharmaceutical market, following global safety concerns.
The patent expiry of semaglutide drugs will create a massive Rs 50 billion+ revenue opportunity for generic makers in India and globally over the next 12-15 months, boosting diabetes treatment access. Read the full analysis.
Patent expiry of semaglutide drugs will create a Rs 50+ billion revenue chance for generic pharma firms in 12-15 months. Prices may drop up to 75%, boosting patient access. Read the full analysis.
Bihar's Mines Minister Vijay Kumar Sinha suspends Darbhanga district mines inspector for serious irregularities. State to launch mass awareness camps on legal sand mining from Jan 16. Report illegal activities on helpline.
As patents expire, Indian drugmakers like Lupin and Ajanta Pharma are forging licensing and distribution deals for GLP-1 obesity drugs. The market is set for explosive growth. Explore the key partnerships and market dynamics.
Aurobindo Pharma strengthens its domestic formulations market with a ₹325 crore acquisition of Khandelwal Laboratories' non-oncology business. The deal includes 23 established brands and boosts presence in pain & anti-infective segments. Read more.
India's drug regulator CDSCO refuses to disclose risk-based inspection details under RTI, sparking debate on transparency vs. commercial interests. Experts warn this secrecy endangers public health.
Nvidia's massive $20 billion licensing agreement with Groq secures key AI inference technology and talent. Discover the deal's specifics, founder's windfall, and what's next.
Nvidia's non-exclusive licensing deal with AI chip startup Groq, valued at ~$20B, triggers major payouts for shareholders & employees. Founder, CEO, and 90% of staff join Nvidia, while Groq continues independently. Explore the details.
Fermenta Biotech Ltd. has been recognized as one of India's Best Workplaces in Pharmaceuticals, Healthcare & Biotech 2024 by Great Place To Work. Discover what makes their culture stand out.
India sets a 2026 health roadmap focusing on stringent drug quality, TB elimination, obesity, and a ₹4,200 crore innovation push. Will execution match ambition?
Pune's residential areas like Kalyaninagar & Baner face chaos from pubs in housing zones. Residents cite noise, safety issues & crippled infrastructure. Read about their fight for peace.
India's music creator revenues hit €80.5M in 2024, per CISAC. Yet, heavy reliance on streaming & under-licensed sectors threaten long-term growth. Industry demands fair royalties.
Everfast Freight Forwarders launches a major cold chain expansion in India, enhancing storage for medicines and vaccines. Discover how this investment supports healthcare logistics.
Netflix will pull more than 100 of its Original series and films in 2026 as licensing deals expire. Find out which popular shows like The Last Kingdom and She-Ra are leaving.
JioHotstar's new series 'Pharma' ignites public debate on drug pricing, ethics, and accessibility in India's healthcare system. Read the full analysis.
India's proposed mandatory AI licensing aims to protect creators' rights but risks stifling innovation. Experts weigh the complex trade-offs in this new policy.
India's pharmaceutical industry gears up for a critical 5-year phase from 2026, aiming to become a $500 billion innovation hub by 2047. Learn how it plans to tackle challenges and seize opportunities.
Afghan Health Minister admits strained Pakistan ties, pivots to India for reliable medicine and vaccine supplies. A major shift in regional health diplomacy unfolds. Read the full analysis.
US President Donald Trump secures agreements with nine major pharmaceutical companies to reduce Medicaid and cash-pay drug prices, aiming to align US costs with other wealthy nations. Details inside.
India plans to replace 5-year medical device licenses with perpetual approvals and standardize lab testing to cut compliance costs and attract investment. Read more.
Odisha CM Mohan Majhi positions state as top pharma & medical devices investment destination. New policy & parks attract Rs 7,043 crore proposals, 45 MoUs signed. Read more.
India's proposed blanket license for AI training data could raise costs, hurt creators, and drive startups abroad. Experts urge a balanced approach to foster innovation.
Shark Tank India's Anupam Mittal comments on Ozempic's India launch, its ₹8,800/month price, and the 2026 patent expiry that could 5x the market. Read his take on fitness shortcuts vs. discipline.
Indian government intensifies scrutiny on pharmaceutical sector, auditing 700+ cough syrup manufacturers. Health Ministry reveals 19 drug samples collected for testing amid child safety concerns. Read the full report.